News
Heron Therapeutics' Q1'25 earnings show Cinvanti leading, Zynrelef's 60% sales growth, raised EBITDA guidance & future potential. Learn more on HRTX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback